Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safusidenib in IDH1-Mutant Glioma
NCT05303519Phase 3Recruiting
- Sponsor
- Nuvation Bio
- Start
- Jun 2023
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of safusidenib in glioma, astrocytoma, Oligodendroglioma (OG), sponsored by Nuvation Bio. Started Jun 2023; status: recruiting.
02
Drugs
safusidenib
03
Conditions
gliomaastrocytomaOligodendroglioma (OG)
Beyond the preview
Go deeper on NCT05303519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05303519.